Granovsky v. Pfizer, Inc.

631 F. Supp. 2d 554, 2009 U.S. Dist. LEXIS 57470, 106 Fair Empl. Prac. Cas. (BNA) 1207, 2009 WL 1940765
CourtDistrict Court, D. New Jersey
DecidedJuly 7, 2009
DocketCiv. 08-2280 (WHW)
StatusPublished
Cited by13 cases

This text of 631 F. Supp. 2d 554 (Granovsky v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Granovsky v. Pfizer, Inc., 631 F. Supp. 2d 554, 2009 U.S. Dist. LEXIS 57470, 106 Fair Empl. Prac. Cas. (BNA) 1207, 2009 WL 1940765 (D.N.J. 2009).

Opinion

OPINION

WALLS, Senior District Judge.

Plaintiff moves to remand this action to the Superior Court of New Jersey, Law Division, Bergen County. She argues that Defendant Pfizer, Inc. improperly removed it from state court in violation of the requirements of 28 U.S.C. § 1446(a) and (b).

FACTS AND PROCEDURAL BACKGROUND

I. Underlying Dispute

The following is a brief summary of the underlying dispute as alleged by plaintiff: Granovsky had been employed by Pfizer in New Jersey for a number of years as an analytical chemist. She reported to and worked under the control of Pfizer management, but was employed by Pfizer through Kforce, a staffing company. 1

In 2004, Granovsky filed an EEO complaint with Pfizer and Kforce alleging that the conduct of her immediate Pfizer supervisor, following the end of a romantic relationship with plaintiff, had created a sexually hostile work environment. (Compl. at ¶¶ 11 — 44). The 2004 complaint was ostensibly resolved when Granovsky accepted reassignment to another work group reporting to another Pfizer supervisor. (Compl. at ¶ 15). However, as a result of the former supervisor’s past and continuing conduct and ongoing hostility of Pfizer management attributable to her having filed an EEO complaint, Granovsky’s personal and professional reputation in the workplace suffered. She alleges that she was denied assignments and employment opportunities within Pfizer as a result of this hostile treatment. (Compl. at ¶¶ 17-19). Pfizer and Kforce terminated Granovsky on April 7, 2006 without stating a reason. (Compl. at ¶ 21).

On April 1, 2008, Granovsky filed her state law complaint in the Superior Court of New Jersey, Law Division, Bergen County. See Alla Granovsky v. Pfizer, Inc. and Kforce, Inc., Civil Action No. L-2546-08. Granovsky’s state law complaint against Pfizer and Kforce seeks redress for the retaliatory, discriminatory and wrongful termination of her employment. *557 The six count complaint pleads claims of sex discrimination, retaliation, blacklisting and aiding and abetting under the New Jersey Law Against Discrimination (LAD) (Compl., Counts I, II, III and IV); tortious interference under New Jersey law (Compl., Count V) and violation of New Jersey public policy (Compl., Count VI).

II. Procedural History

The following procedural history is undisputed unless otherwise stated. On April 8, 2008, Granovsky served both Pfizer and Kforee with a summons, the filed complaint, civil case information statement, and New Jersey Superior Court Track Assignment Notice via certified mail pursuant to New Jersey Superior Court Civil Practice Rule 4:4-4(c). (PL’s Exs. 1, 2, 3, 4, 5, 6, and 7). The service upon each defendant was accompanied by an April 8, 2008 transmittal letter addressed to their respective chief executive officers. The letters informed Pfizer and Kforee that they were each being served pursuant to R. 4:4-4(c). (Pi’s Exs. 2 and 6).

According to plaintiff, Pfizer and Kforee each received the certified mail service authorized under R. 4:4-4(c), including the summons and complaint, on April 10, 2008. (Pi’s Exs. 8, 9 and 10). Pfizer disputes this date and states in its supporting affidavit that the summons and complaint were received on April 14, 2008. (Arencibia Aff. at ¶ 4). This factual dispute is ultimately insignificant since Pfizer’s May 8, 2008 notice of removal was within 30 days of either the April 10 or April 14 receipt date.

On May 8, 2008, Pfizer filed its notice of removal, including copies of the process served upon it, but not the process served upon Kforee. (PL’s Ex. 10). Pfizer’s notice of removal represented that “Kforce’s counsel, Marvin L. Weinberg, Esq. of Fox Rothschild LLP, advised that Kforee consents to the removal of this matter.” (PL’s Ex. 10 at ¶ 4). However, at the time Pfizer filed its notice of removal, neither Pfizer nor Kforee had filed any other writing or evidence from Kforee to establish Kforce’s consent to the removal.

Pfizer’s notice of removal stated that both it and Kforee had been served with a summons and complaint and that Pfizer had “affected [sic] removal within thirty (30) days of service upon it and Kforee of a paper from which it could first be ascertained that this action is removable.” (PL’s Ex. 10 at ¶¶1, 2, 3, and 5). The notice contained a footnote stating, “We note neither Defendant was properly served with the summons and complaint.” (PL’s Ex. 10 at n. 1).

Pfizer’s notice of removal is premised on diversity jurisdiction under 28 U.S.C. § 1332. (PL’s Ex. 10 at ¶ 8). Granovsky’s counsel received Pfizer’s removal papers on May 9, 2008. (Hermann Aff. at ¶ 6). On May 14, 2008, Kforee entered an appearance and moved for additional time to answer. (Hermann Aff. at ¶ 10). On May 15, 2008, Granovsky’s counsel wrote to counsel for Pfizer and Kforee. (PL’s Ex. 12). The letter advised:

“It appears the case has not been properly removed from state court in accordance with the requirements of 28 U.S.C. § 1446(a) and (b) within the statutorily permitted 30 day time period following defendants’ receipt of the state court complaint. More specifically, the rule of unanimity was not met. Pfizer cannot speak for Kforee in filing a notice of removal. Since Kforee did not sign the removal petition or otherwise file a consent to removal within the provided time period, remand to state court is appropriate.” (Id.)

The letter further informed Pfizer and Kforee that unless the parties could agree to a consent order remanding the case, *558 Granovsky intended to file a motion to remand.

On May 16, 2008, Pfizer’s counsel responded with a letter citing Murphy Brothers, Inc. v. Michetti Pipe Stringing, Inc., 526 U.S. 344, 350, 119 S.Ct. 1322, 143 L.Ed.2d 448 (1999) to plaintiffs lawyer arguing that “since formal service has not occurred the thirty day removal period has not even begun to run.” (PL’s Ex. 13). The letter further stated that Pfizer’s notice of removal “represented that counsel for Kforce consented to the removal of this matter. Such a representation is sufficient for removal purposes. There is no requirement that Kforce sign the removal petition or otherwise file a consent to the removal.” (Id.).

On May 23, 2008, Granovsky’s counsel answered Pfizer’s counsel’s May 16, 2008 letter, disputing assertions therein; citing Michaels v. State of New Jersey, 955 F.Supp. 315, 321 (D.N.J.1996) and other authority requiring that each defendant either formally join in the notice of removal or provide unambiguous written evidence to the Court in a timely fashion; and advising that Granovsky would proceed with a motion to remand. (PL’s Ex. 14). The letter noted: “Pfizer’s removal papers were signed pursuant to Rule 11 and filed with the federal and state courts.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
631 F. Supp. 2d 554, 2009 U.S. Dist. LEXIS 57470, 106 Fair Empl. Prac. Cas. (BNA) 1207, 2009 WL 1940765, Counsel Stack Legal Research, https://law.counselstack.com/opinion/granovsky-v-pfizer-inc-njd-2009.